Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients.

ABSTRACT:

Background

It is well-known that lymphoma patients undergoing treatment are at risk of hepatitis B virus (HBV) reactivation. This study aims to explore the risk factors for HBV reactivation in lymphoma patients who tested negative for both hepatitis B surface antigen (HBsAg) and HBV DNA before treatment, during their course of therapy. It provides clinical evidence for early intervention in HBV reactivation and rational preventive antiviral treatment.

Methods

From January 2019 to December 2021, a total of 1,229 patients were diagnosed with lymphoma at Guangdong Provincial People's Hospital. Among them, 616 patients who tested negative for both HBsAg and HBV DNA and underwent therapy were recruited for the study. The recruited patients had a median age of 53.9 years (range: 1

SUBMITTER: Chen L 

PROVIDER: S-EPMC12443279 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature